Healthcare + med tech
Axonics
Acquired for $3.7 billion by Boston Scientific
A first-to-market sacral neuromodulation device. We rebuilt the direct-to-consumer campaign into a four-tier structure and ran a daily side-by-side report so the client could compare it against their old strategy, apples to apples.
$3.7Bacquisition by Boston Scientific · $24.3M in DTC sales attributed, 97% jump in device implants
“Every agency says they’re the best at what they do. With MB Health, that’s actually true. How they present themselves is how they show up. Every day.” Manar Sleiman, Axonics








































